 |
|
Pharmacotherapy of Impaired Affect in Recovering Schizophrenic Patients
Gerard E. Hogarty, MSW;
Joseph P. McEvoy, MD;
Richard F. Ulrich, MS;
Ann Louise DiBarry, MSN;
Partricia Bartone, MSN;
Susan Cooley, MEd;
Kathleen Hammill, MSN;
Mary Carter, PhD;
Mark R. Munetz, MD;
James Perel, PhD
Arch Gen Psychiatry. 1995;52(1):29-41.
Abstract
| |
Background
Prominent and persistent anxiety, depression, and/or negative features characterize a substantial minority of recovered or residually psychotic schizophrenic outpatients and contribute to poor outcome. Because extrapyramidal side effects of typical neuroleptic medications often resemble such features, we first systematically studied the contribution of extrapyramidal side effects to these problems and their treatment. For patients who remained distressed, controlled trials of supplemental thymoleptics were undertaken.
Methods
In trial 1, 92 distressed (depressed and/or anxious) patients and 36 patients in a defect state (patients with negative symptoms) participated in a double-blind, intramuscular challenge that compared centrally acting benztropine mesylate with peripherally acting glycopyrrolate. In trial 2,57 distressed patients and 22 patients in a defect state were randomly assigned to a double-blind, neuroleptic medication dose-reduction group. In trial 3,57 chronically distressed patients who were maintained on a low dose of fluphenazine decanoate were randomly assigned to a supplemental desipramine hydrochloride, lithium carbonate, or placebo group under double-blind conditions for 12 weeks.
Results
For patients who were already maintained on antiparkinsonian medication, impaired affect was not resolved by additional benztropine. Only distressed patients with a family history of severe mental disorder (often affective) showed improvement with neuroleptic medication dose reduction. Patients in the defect-state group reported less dysphoria on a reduced neuroleptic medication dose, but negative symptoms persisted. Desipramine improved diverse aspects of mood and residual psychoticism, possibly as a prophylaxis against minor affective exacerbations. Depression improved in women only. Lithium positively affected multiple indexes of anxiety and anxious depression.
Conclusion
Most often, persistent affective impairments are neither resistant extrapyramidal side effects nor characterological traits. Thymoleptics improve the non-phasic, chronic types of anxiety and depression in contrast to the acute, episodic forms, for which little support can be found in the literature.
Author Affiliations
From the Western Psychiatric Institute and Clinic, University of Pittsburgh (Pa0 School of Medicine. Dr McEvoy is now with the Duke University Medical Center, Durham, NC, and Dr Munetz is now with the Northeastern Ohio Universities College of Medicine, Rootstown.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Cognitive Enhancement Therapy for Early-Course Schizophrenia: Effects of a Two-Year Randomized Controlled Trial
Eack et al.
Psychiatr. Serv. 2009;60:1468-1476.
ABSTRACT
| FULL TEXT
Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial
Chakos et al.
Psychiatr. Serv. 2006;57:1094-1101.
ABSTRACT
| FULL TEXT
Cognitive Enhancement Therapy for Schizophrenia: Effects of a 2-Year Randomized Trial on Cognition and Behavior
Hogarty et al.
Arch Gen Psychiatry 2004;61:866-876.
ABSTRACT
| FULL TEXT
Three-Year Trials of Personal Therapy Among Schizophrenic Patients Living With or Independent of Family, I: Description of Study and Effects on Relapse Rates
Hogarty et al.
Focus 2004;2:146-157.
ABSTRACT
| FULL TEXT
Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic Agents
Siris
Am. J. Psychiatry 2000;157:1379-1389.
ABSTRACT
| FULL TEXT
Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents
Millan et al.
J Psychopharmacol 2000;14:114-138.
ABSTRACT
Treatment of Schizoaffective Disorder and Schizophrenia With Mood Symptoms
Levinson et al.
Am. J. Psychiatry 1999;156:1138-1148.
ABSTRACT
| FULL TEXT
Depressive Signs and Symptoms in Schizophrenia: A Prospective Blinded Trial of Olanzapine and Haloperidol
Tollefson et al.
Arch Gen Psychiatry 1998;55:250-258.
ABSTRACT
| FULL TEXT
Three-Year Trials of Personal Therapy Among Schizophrenic Patients Living With or Independent of Family, I: Description of Study and Effects on Relapse Rates
Hogarty et al.
Am. J. Psychiatry 1997;154:1504-1513.
ABSTRACT
| FULL TEXT
Three-Year Trials of Personal Therapy Among Schizophrenic Patients Living With or Independent of Family, II: Effects on Adjustment of Patients
Hogarty et al.
Am. J. Psychiatry 1997;154:1514-1524.
ABSTRACT
| FULL TEXT
Treating the Postpsychotic Phase of Schizophrenia
JWatch Psychiatry 1995;1995:7-7.
FULL TEXT
|
